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Functional Expression of 
Cardiac and Smooth Muscle 
Calcium Channels 
F. Hofmann, M. Biel, Ε. Bosse, V. Flockerzi, 
P. Ruth, and A. Welling 
Η o rmones and neurotransmit ters play an i m p o r t a n t role i n regulat­
i n g the force o f cont rac t ion i n heart and smooth muscle. T h e force o f 
cont rac t ion o f the heart is p r imar i l y con t ro l l ed by the ca lc ium i n f l u x across 
the cell membrane d u r i n g the act ion potent ia l , whereas that o f smooth 
muscle is in i t ia l ly con t ro l l ed by the release o f ca lc ium f r o m int racel lu lar 
stores fo l lowed by a ca lc ium i n f l u x f r o m the extracel lular space t h r o u g h 
voltage-dependent ca lc ium channels. T h e best-characterized pathway for 
ca lc ium entry i n b o t h cell types are voltage-dependent L-type ca lc ium chan­
nels, wh ich activate at membrane po ten t ia l a r o u n d —30 mV, inactivate 
slowly, and are expressed i n many dif ferent cell tissue (1 ) . These channels 
are readily b locked by classical organic ca lc ium channel blockers (CaCBs) 
n i fed ip ine [a 1,4-dihydropyridine ( D H P ) ] , verapamil [a phenyla lkylamine 
( P A A ) ] , and d i l t iazem (a benzod iazep ine ) ( 2 - 4 ) . 
Cardiac and smooth muscle ca lc ium channels have c o m m o n electro­
physiological characteristics, yet they are regulated dis t inct ly by CaCBs 
and hormones. T h e ß - a d r e n e r g i c receptor agonist i soproterenol increases 
cardiac calc ium cur ren t 3- to 7-fold ei ther by cAMP-dependent phosphoryla-
t ion o f the channel (5, 6 ) , o r t h r o u g h the activated α - s u b u n i t o f the t r imer ic 
glutamyl transpeptidase (GTP) b i n d i n g p ro t e in G s (7, 8 ) , or by the com­
b ined action o f G a s and the catalytic subuni t o f c A M Ρ kinase (9) . T h e L -
type calc ium cu r r en t o f isolated tracheal smooth muscle cells is s t imulated 
also by the act ivat ion o f the ß - a d r e n e r g i c receptor (10) . This ß - r e c e p t o r 
effect is no t media ted by c A M P kinase, bu t by the d i rec t effect o f a G-
p ro t e in . These and fur ther results (11) lead to the conclus ion that the 
smooth and cardiac muscle ca lc ium channels maybe regulated i n vivo by the 
α - s u b u n i t o f a G-protein, bu t only the cardiac channel by cAMP-dependent 
phosphory la t ion . T h e p r imary sequences o f the cardiac and a putative 
smooth muscle ca lc ium channel have been iden t i f i ed by c l o n i n g the i r 
HOFMANN ET AL. 
cDNAs. T h e sequences o f these clones are very similar, and they d i rec t the 
expression o f L-type ca lc ium channels o f very s imilar propert ies . 
Molecular Identity of Cardiac and Smooth Muscle 
Calcium Channels 
General Composition of the Calcium Channel 
In i t ia l ly , the L-type ca lc ium channel was pu r i f i ed f r o m skeletal muscle. 
T h e p u r i f i e d c o m p l e x c o n t a i n s f o u r p r o t e i n s (F ig . 1 ) : the a r s u b u n i t 
(212,018 D a ) , w h i c h contains the b i n d i n g sites for all k n o w n CaCBs and 
the ca lc ium c o n d u c t i n g pore; the in t race l lu la r located ß - s u b u n i t (57,868 
D a ) ; the t ransmembrane 7-subunit (25,058 D a ) ; and the a r / 6 - s u b u n i t , a 
disulf ide- l inked d i m e r o f 125,018 Da ( 2 - 4 and references c i ted there) . 
Reconst i tu t ion o f the pu r i f i ed complex i n t o p h o s p h o l i p i d bilayers resulted 
i n func t iona l ca lc ium channels that are reversibly b locked by CaCBs and 
Figure 1. Proposed structure of the cardiac calcium channel. The putative 
transmembrane configuration of individual subunits is based on hydropathicity 
analysis of the deduced primary sequences, I, II, III, and IV, proposed repeats of 
calcium channel a r subunit ; + , transmembrane amphipathic α-helix, respectively, 
the proposed voltage-sensing helix of the channel; ( £ ) , putative cAMP kinase 
phosphorylation sites; only two of several phosphorylation sites are shown in the 
sequence of the α,-subunit; s, disulfide bridge between the transmembrane δ and 
the extracellular-located a2-subunit; SS1-SS2, suggested part of the channel pore. 
The extracellular space is above the horizontal lines. Note that a 7-subunit that is 
present in the skeletal muscle calcium channel has not been identified in cardiac 
tissue. 
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are m o d u l a t e d by cAMP-dependent phosphory la t ion ( 1 2 - 1 5 ) . T h e pr imary 
sequences o f these proteins have been deduced by c l o n i n g the i r corres­
p o n d i n g cDNAs f r o m rabbit skeletal muscle ( 1 6 - 2 0 ) . Us ing these cDNAs 
as probes, different α Γ and ß - s u b u n i t s have been c loned f rom heart and 
smooth muscle. 
The Calcium Conducting α] -Subunit 
T h e L-type calc ium channel a r s u b u n i t s are encoded by three dif ferent 
genes ( C a C h l - 3 ) (see refs. 21 and 22 for nomencla ture , and Fig. 2 ) . T h e 
p r o d u c t o f the C a C h l gene occurs i n skeletal muscle; the p roduc t o f the 
CaCh2 gene is expressed i n heart, smooth muscle, endocr ine , and neurona l 
cells, and that o f the CaCh3 gene is present i n neuroendocr ine and neu­
rona l cells. The a r s u b u n i t s f r o m cardiac (CaCh2a) (23) and smooth muscle 
























Figure 2. Developmental tree of cloned and functionally expressed calcium 
channel a r subunits. The identification of the calcium channel a r subunits follows 
the order of publication and includes only those clones that have been expressed 
functionally (21, 22, 25). The Snutch nomenclature (52) for the brain calcium 
channels does not include the CaChl gene. The CaCh2, CaCh3, CaCh4, and 
CaCh5 genes correspond to Snutch genes C, D, A, and B, respectively. 
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(CaCh2b) (24) are splice products o f the second gene (CaCh2) (Fig. 3) . 
T h e CaCh2b sequence is 95% ident ica l w i t h the CaCh2a sequence and 
differs only at four sites. T h e use o f alternative exons (25) results i n different 
IVS3 segments (Fig. 3, site D ) . D i e b o l d and coworkers (26) r epo r t ed thai 
the two exons are different ia l ly expressed d u r i n g cardiac development . 
N o r t h e r n blots using the CaCh2a and CaCh2b specific 5'-sequences as 
p r o b e s , a n d p o l y m e r a s e c h a i n r e a c t i o n analysis o f the n o n i d e n t i c a l 
sequences, showed that the sequence o f cardiac site A is present on ly in 
cardiac muscle p o l y A + m R N A , whereas the sequences o f the smooth muscle 
sites A , B, and C are present i n tracheal, l u n g , and cardiac po lyA* m R N A 
(27) . This d i s t r ibu t ion o f the CaCh2a and CaCh2b sequences s trongly favors 
the conclusion that the CaCh2a p ro t e in is a cardiac muscle-specific α Γ 
subuni t , whereas the CaCh2b p r o t e i n is a smooth muscle-specific a r sub -
u n i t (27) . 
c D N A o f the t h i r d gene (CaCh3) was isolated f r o m neu rona l and 
endocr ine tissues and represents a neuroendocr ine specific L-type ca lc ium 
channel (28, 29) , whereas the gene products o f the f o u r t h and fifth gene 
(CaCh4 and CaCh5) have been f o u n d exclusively i n neurona l tissues. Cal­
c i u m channels transiently expressed f r o m cRNA o f CaCh4 induce h igh-
voltage-activated, ca lc ium currents insensitive to n i fed ip ine and ω-cono-
t o x i n , bu t i n h i b i t e d by a m i x t u r e o f toxins f r o m the funne l web spider, 
thus character izing this channel as a P-type calc ium channel (30) . The 
gene p roduc t o f CaCh5 binds and is irreversibly b locked by p i comola r 
concentrat ions o f ω - c o n o t o x i n iden t i fy ing the CaCh5 p ro t e in as a neurona l 
N-type ca lc ium channel (31 , 32) . 
Additional Subunits 
a278-Subunit 
T h e skeletal muscle a 2 - / ö - s u b u n i t is a glycosylated membrane p ro t e in 
o f 125,018 Da (17) that is apparently h i g h conserved i n most tissues. I n 
I II I I I IV 
Figure 3. Sequence differences between the CaCh2a (cardiac) and CaCh2b 
(smooth muscle) α,-subunit. The sequences that are different in the smooth 
muscle clone are shown in black and are identified by A, B, C, and D. 
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skeletal muscle the p r imary p r o t e i n p r o d u c t o f the a 2-/8-gene is processed 
pos t - t rans la t ional ly by proteolysis r e su l t i ng i n an a 2 - p r o t e i n c o n t a i n i n g 
a m i n o acids 1 t h r o u g h 934, and a δ - p r o t e i n con ta in ing a m i n o acids 935 
t h r o u g h 1080 (33) (see Fig. 1) . T h e t ransmembrane 8-subunit anchors the 
extracel lular located a 2 -p ro te in by disulfide bridges to the plasma mem­
brane (34) . I m m u n o b l o t (35) and N o r t h e r n b l o t (17, 27) show that similar 
or iden t ica l a 2 - /8-subunits exist i n skeletal muscle, heart , b ra in , vascular, 
and intest inal smooth muscle. Coexpression o f the cardiac α , - s u b u n i t wi th 
the skeletal muscle a ^ / δ - p r o t e i n i n Xenopus oocytes increases slightly the 
cu r r en t density (23, 26) and decreases 2-fold channel activation t ime (36) . 
I t is n o t clear whether these modu la to ry effects are physiologically relevant 
propert ies o f the a 2 - /8 -p ro te in or restr icted to the Xenopus oocyte expres­
sion system. 
-y-Subunit 
N o r t h e r n blots and screening o f cardiac c D N A libraries failed to 
ident ify the presence o f the y-subunit i n cardiac or smooth muscle p o l y A + 
m R N A , suggesting that this p ro t e in may be specific for skeletal muscle. 
ß-Subunit 
T h e skeletal muscle ß - s u b u n i t ( C a B l ) is an in t race l lu lar located mem-
brane p ro t e in consist ing o f 524 a m i n o acids (18) . Its deduced amino acid 
sequence contains stretches o f hep tad repeat structure that are characteris-
tic o f cytoskeletal proteins. T w o o ther genes (CaB2 and CaB3) encod ing 
ß - p r o t e i n s di f ferent f r o m the skeletal muscle ß - s u b u n i t have been isolated 
f r o m a cardiac c D N A l ibrary (37) . T h e i r deduced amino acid sequences 
show an overall homology to C a B l o f 7 1 % (CaB2) and 66.6% (CaB3). 
Dif ferent ia l sp l ic ing o f the p r imary transcript o f C a B l results i n at least 
four isoforms: C a B l a t h r o u g h C a B l d (18, 32, 38) . C a B l a is expressed in 
skeletal muscle, whereas the o ther isoforms are expressed i n b ra in . Four 
d i f ferent splice variants have been characterized for the CaB2 gene (CaB2a 
t h r o u g h CaB2d); CaB2a and CaB2b have been isolated f rom a rabbi t cardiac 
c D N A library, whereas CaB2c and CaB2d have been c loned f r o m rabbi t 
and rat bra in l ibraries (37, 39) . L i k e the C a B l gene, the CaB2 and CaB3 
genes are expressed tissue specifically, w i th transcripts o f CaB2 exist ing 
abundant ly i n heart and to a lower degree i n aorta, trachea, and l ung . 
Transcripts o f CaB3 genes are expressed i n b ra in and smooth muscle-
con ta in ing tissues, such as aorta, trachea, and l u n g (37) . This suggests that 
the CaB3 gene p roduc t may be expressed p redominan t ly i n neurona l and 
smooth muscle cells. T h e deduced a m i n o acid sequence o f the skeletal 
muscle ß - s u b u n i t ( C a B l ) contains several phosphory la t ion sites. Two o f 
these sites, Ser-182 and Thr-205, are phosphoryla ted i n v i t ro by cAMP-
dependent p ro t e in kinase (18, 40) . T h e equivalent to Thr-205 is conserved 
in the "ca rd iac" ß - s u b u n i t (Thr-165 i n CaB2a and Thr-191 i n CaB2b) , bu t 
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is no t present in the " s m o o t h muscle" ß - s u b u n i t , CaB3. T h e sequence 
fo l l owing this potent ia l phosphory la t ion site is h igh ly variable and deter-
mines several splice variants (37) . T h e absence o f a putative cAMP kinase 
p h o s p h o r y l a t i o n site i n the va r i ab l e r e g i o n o f the " s m o o t h " musc le 
ß - s u b u n i t and its presence i n the "ca rd iac" muscle ß - s u b u n i t maybe respon-
s ible f o r the tissue-specific r e g u l a t i o n the L- type c a l c i u m c u r r e n t s by 
cAMP kinase. 
Expression of the Cloned Cardiac and Smooth Muscle 
Calcium Channel ατ-Subunits 
T h e two alternative splice variants CaCh2a and CaCh2b have been 
expressed transiently i n Xenopus oocytes (23, 24, 36) and stably i n Chinese 
hamster ovary ( C H O ) cells (41 ,42) . I n e i ther system they di rect the synthesis 
o f func t iona l L-type calcium channels. C H O cells transfected wi th e i ther 
CaCh2a or CaCh2b c D N A express 1,4-dihydropyridine b i n d i n g sites that 
b i n d isradipine stereospecifically w i t h an affinity o f 0.1 n M (Table 1). 
B i n d i n g o f isradipine is modu la t ed allosterically by rf-m-diltiazem (41) . 
Nontransfected cells, or C H O cells transfected w i t h a c D N A unrela ted to 
Table 1. Electrophysiological properties of the expressed cardiac (CaCh2a) and 






DHP binding sites (fmol/mg) 73.5 ± 5.4 (3) 141 + 3 (3) 
Affinity (nM) 0.2 0.1 0.04 (3) 
Current density (μΑ/cm 2 ) 
- B a y Κ 8644 - 1 5 . 2 ± 4.4 (9) - 1 3 . 3 1.9 (11) 
+ Bay Κ 8644 - 6 8 . 2 ± 16.i 6 (8) - 4 6 . 7 5.4 (14) 
Increase with Bay Κ 8644 at 10 mV (fold) 9.3 ± 2.6 (8) 5.5 ± 0.8 (11) 
9 0 % ttp (msec) 7.9 ± 0.8 (9) 12.5 ± 1.5 (12)* 
dec,oo (%) 87.1 ± 2.7 (9) 84.7 ± 1.8 (11) 
Vo.5inact (mV^ + 5.2 ± 3.6 (9) + 5.1 ± 4.0 (5) 
V0.5act (mV) + 8.3 ± 0.8 (9) + 9.5 + 0.8 (5) 
CHO cells were stably transfected and inward currents were measured as described 
in Fig. 4 legend. The current is the maximum current from the current-voltage 
relation divided by the cell capacitance. The increase in lB < 3 caused by Bay Κ 8644 
was calculated for each cell at a membrane potential of 10 mV. 9 0 % ttp, time for 
\B a to reach 90% of its peak amplitude at 10 mV; dec 1 0 0 / decrease in l B a from peak 
to the level observed 100 msec after the beginning of depolarization to 10 mV; 
V 0 5 inact, half-maximal inactivation voltage, V0.5act, half-maximal activation voltage. 
Values are given as mean ± SEM, with the number of cells in parentheses. The DHP 
binding sites were determined with (3H)isradipine. 
*Significantly different from the CaCh2a value at P< 0.05. 
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the ca l c ium channel , do no t possess D H P b i n d i n g sites or L-type calc ium 
cur ren t , whereas cells expressing the cardiac or smooth muscle a r s u b u n i t 
have L-type ca lc ium cu r r en t (Fig. 4 ) . The basic electrophysiological charac­
teristics o f these two splice variants o f the CaCh2 gene are almost ident ica l 
(Table 1) . Bo th channels are b locked by isradipine and are s t imulated 5-
to 10-fold by Bay Κ 8644 at 10mV (Table 1). Act iva t ion o f the channel by 
Bay Κ 8644 shifts the m a x i m a l inward cu r ren t by 10 m V to 10 mV. I n the 
presence o f Bay Κ 8644 and 30 m M BaCL, half-maximal activation (V 0 .5 a a ) 
occur red at 9.5 and 8.3 m V for the smooth and cardiac muscle, respectively. 
U n d e r the same condi t ions , half-maximal steady-state inact ivat ion (Vo.5 i n. i a) 
occur red at 5.1 and 5.2 mV, respectively. B o t h channels inactivate faster 
i n the presence o f C a 2 + than B a 2 + (i.e., inact ivat ion o f the CaCh2 channel 
is voltage- and calc ium-dependent as k n o w n for the native L-type ca lc ium 
channe l ) . T h e only difference no ted was faster activation for cardiac than 
for smoo th muscle channels i n the absence and presence o f the Bay Κ 
8644. Func t iona l expression o f chimeras o f the skeletal and the cardiac 
muscle α , - s u b u n i t showed that repeat I determines the activation t ime o f 
the ch imer i c channel ; that is, a slow activation u p o n membrane depolariza­
t ion w i t h the repeat f r o m skeletal muscle, and rap id activation wi th that 
f rom cardiac muscle (43) . I t is possible that the difference i n activation 
times between the cardiac and smooth muscle channels is caused by the 
difference in the IS6 sequence (site Β i n Fig. 3 ) . T h e open probabi l i ty o f 
the expressed smooth muscle channel increases wi th membrane depolariza­
t ion . T h e channel has a single-channel conductance o f 26 pS i n 80 m M 
BaCL (41) . These data show that the a r s u b u n i t alone is sufficient to f o r m 
a physiologically relevant ca lc ium channel that has the propert ies o f a 
smooth or cardiac muscle L-type ca lc ium channel . 
Stable expression o f the CaCh2b channel w i t h the skeletal muscle 
ß - g e n e ( C a B l ) , increased i n paral le l the n u m b e r o f D H P b i n d i n g sites and 
the a m p l i t u d e o f whole-cell b a r i u m curren t suggesting that the ampl i tude 
o f t he i n w a r d c u r r e n t is d i r e c t l y r e l a t e d to the dens i ty o f expressed 
oi |-protein (35) . In add i t i on the coexpression o f the ß - s u b u n i t decreased 
channel activation t ime 2-fold and shifted the voltage dependence o f steady-
state inac t iva t ion by 18 mV, to — 13 m V , wi thou t affecting sensitivity to the 
ca lc ium channel agonist Bay Κ 8644. 
Modulation of the Expressed Calcium Channel 
I n heart, ß - a d r e n e r g i c s t imula t ion leads to activation o f cAMP kinase 
and an increase in L-type ca lc ium current . Two subunits o f the pur i f i ed 
skeletal muscle ca lc ium channel , the α Γ and ß - s u b u n i t s , are substrates for 
cAMP-kinase i n v i t ro (4, 18, 40, 4 4 - 4 6 ) . Similar potent ia l c A M P kinase 
phosphory la t ion sites are present in the CaCh2 ca lc ium channel sequence 
of b o t h splice variants. T h e poten t ia l impor tance o f these phosphory la t ion 
sites is suppor ted by exper iments that showed that the L-type ca lc ium 
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(nA) 
Figure 4. Electrophysiology of expressed smooth (a, c) and cardiac (b, d) muscle 
a r subunit of the calcium channel. (Top) Barium currents (ΙΒι1) were elicited by a 
140-msec depolarization pulse from a holding potential of - 8 0 mV to 10 mV 
before (a, b) and during the exposure to 2 μ Μ Bay Κ 8644 (c, d). The dashed line 
represents the 0 current level. (Bottom) Current-voltage relationships were 
determined by stepping the membrane potential from - 8 0 mV to the potentials 
indicated. l B a was measured in the absence (a, b) and presence (c, d) of 2 μ Μ Bay 
Κ 8644. CHO cells were stably transfected (41) with the cDNA of the smooth 
muscle α,-subunit of the calcium channel (24) in a p91023(B) expression vector 
or with the cDNA of the cardiac α,-subunit (23) in a pKNH expression vector 
(53). Positive clones were selected for the expression of dihydrofolate reductase or 
with the neomycine derivative G418. Whole-cell current was recorded at room 
temperature in a solution containing (in mM) 82 NaCI, 20 tetraethylommonium-
chloride, 30 BaCI2, 5.4 CsCI, 1 MgCU, 5 HEPES, and 10 glucose, pH 7.4 (NaOH), 
with a pipette solution containing (in mM) 112 CsCI, 1 MgCI>, 3 Na?ATP, 10 
EGTA, and 5 HEPES, pH 7.4 (CsOH). 
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cur ren t expressed i n Xenopus oocytes after the in jec t ion o f rat cardiac 
p o l v ( A + ) R N A is modu la t ed by cAMP-clependent phosphory la t ion (47) . 
However, perfus ion o f a C H O cell expressing the CaCh2b gene wi th 8Br-
c A M P for 5 m i n d i d n o t increase significantly the inward cu r ren t (Fig. 5 ) , 
a l though C H O cells con ta in a func t iona l aclenylyl cyclase, G s , and cAMP-
dependen t p r o t e i n kinase. T h e inward b a r i u m cur ren t was no t affected 
signif icantly w h e n the pipet te so lu t ion conta ined 3 m M ATP7Salme; 3 m M 
ATP7S + 10; or 100 μ Μ 8Br-cAMP or 3 m M ATP7S + 10 μ Μ GTP7S. 
I sopro te reno l failed to increase the b a r i u m cur ren t i n a C H O cell l ine that 
expressed the ß^-aclrenergic receptor at a concent ra t ion o f 1 p m o l / m g 
p ro t e in and the CaCh2b ca lc ium channel . These negative findings suggest 
that the α , - s u b u n i t alone is n o t sufficient to restore h o r m o n a l regula t ion 
o f the native ca lc ium channel . Similar conclusions were reached by Klöck-
ner et al. (48 ) , who injected the cardiac a r s u b u n i t alone or together wi th 
the skeletal muscle ß - s u b u n i t i n t o Xenopusoocyctes. These authors repor ted 
Τ i m e ( s e c ) 
0 6 0 1 2 0 1 8 0 2 4 0 3 0 0 
0 - I 1 1 1 1 . 1 1 1 1 1 
- 5 0 0 J 
Figure 5. 8Br-cAMP has no effect on the barium current. The cell was transfected 
stably with the CaCh2b clone. The barium inward current was measured as 
described in Table 1 footnote. Cells were superfused with (in mM) 79.0 NaCI, 20 
tetraethylammonium, 30 BaCI2/ 5.4 CsCI, 1 MgCI 2 / 10 glucose, and 10 HEPES, pH 
7.4. The pipette solution contained (in mM) 107 CsCI, 3 MgCI 2, 10 EGTA, and 10 
HEPES, pH 7.4, 3 mM ATP7S, and 1 0 μ Μ 8Br-cAMP. The inward current at 10 
mV is shown. The inset shows two current traces taken at time points a and b. 
The small increase in inward current occurring within the first minute was 
observed also in all cells perfused in the absence of ATP7S and 8Br-cAMP and is 
caused most likely by the chelation of calcium by EGTA. 
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that cAMP increased b a r i u m currents only i n Xenopus oocytes expressing 
the card iac a ] - a n d the ske le ta l musc le ß - s u b u n i t ( 4 8 ) . H o w e v e r , the 
repor ted inward currents were small and the i r sensitivity toward Bay Κ 8644 
or a 1,4-dihydropyridine b locker was no t tested. Therefore , these authors 
d i d n o t exclude the possibility that the ß - s u b u n i t associated w i t h the endoge-
nous Xenopus oocyte ca lc ium channel (36, 49) , w h i c h is insensitive to the 
1,4-dihydropyridines, is s t imulated by c A M P i n the presence o f the skeletal 
musc le s u b u n i t s ( 5 0 ) . P e r f u s i o n o f C H O cells e x p r e s s i n g t h e CaCh2 
o t r subun i t and the skeletal muscle ß - s u b u n i t w i t h cAMP or 8Br-cAMP had 
no effect o n the size o f the inward current , suggesting that at least i n C H O 
cells the c o m b i n a t i o n o f these two subunits, w h i c h are n o t expressed i n 
vivo in the same tissue, does n o t restore h o r m o n a l c o n t r o l o f the cardiac 
ca lc ium channel . These negative results are unexpla ined , so far. T h e cAMP 
kinase activity o f Xenopus oocytes is h ighe r than i n most cells and cou ld 
phosphorylate constantly the a r s u b u n i t i n vivo. 
Dif ferent results were obta ined w i t h p r o t e i n kinase C. T h e cardiac 
L-type ca lc ium cur ren t is enhanced and subsequently i n h i b i t e d by the 
activation o f p ro t e in kinase C (51) . Act iva t ion o f p r o t e i n kinase C has been 
proposed to mediate the potent ia l effects o f angiotensin I I o n the calc ium 
cur ren t i n heart. T h e skeletal muscle α , - s u b u n i t is rapidly phosphorylatecl 
by p r o t e i n k inase C ( 4 4 ) . C u r r e n t s t h r o u g h t h e C a C h 2 a a r s u b u n i t 
expressed i n Xenopus oocytes were biphasically modu la t ed by activation o f 
p r o t e i n kinase C (49) . In i t i a l ly the cu r ren t increased fo l lowed by a marked 
i n h i b i t i o n . T h e biphasic m o d u l a t i o n was no t m o d i f i e d s ignif icant ly by coex-
pression o f the cardiac a r s u b u n i t w i th the α 2 - / δ - , β-, and y-subunits f r o m 
skeletal muscle, suggesting that p ro t e in kinase C affected the current by 
phosphory la t ion o f the a r s u b u n i t . 
Conclusions 
T h e cardiac and the smooth muscle, high-voltage-act ivated, L-type 
ca lc ium channels are o l igomer ic complexes o f three d i f fe ren t subunits: 
αϊ , α 2 / δ , and β. T h e a r s u b u n i t s are splice products o f the CaCh2 gene. 
T h e a 2 - /o-subuni t may be ident ica l w i t h the skeletal muscle subunit . T h e 
ß - s u b u n i t s are encoded by dif ferent genes. T h e expression o f a tissue-
specific subuni t c o m b i n a t i o n most l ikely results i n the differences i n phar-
macology and func t ion o f the channel . This genetic p o l y m o r p h i s m may 
expla in also the di f ferent regulatory mechanisms and possibly offers a 
chance for ref ined d r u g therapy i n the future . 
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